Company Number 3409832
Registered Charity Number 1071038
Office of the Scottish Charity Regulator SC040914

# **Bowel Cancer UK**

Trustees' Report and Audited Financial Statements
For the year ended 31st December 2015



# BOWEL CANCER UK CONTENTS TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2015



	Page
Trustees' Report	1-19
Independent Auditor's Report	20 – 21
Statement of Financial Activities	22
Balance Sheet	23
Statement of Cash Flows	24
Notes to the Financial Statements	25 – 41



Welcome to the Trustees' Annual Report and Audited Financial Statements for the year ended 31st December 2015.

### **ACHIEVEMENTS AND ACTIVITIES DURING 2015**

### Introduction and key highlights

2015 was another good year for Bowel Cancer UK as we worked with determination to meet our mission to save lives and improve the quality of life of all those affected by bowel cancer. Our key highlights include:

- publishing a new report as part of our 'Never Too Young' campaign. The report
  contained the results of the largest survey ever undertaken of younger bowel cancer
  patients and highlights the progress we have made since we launched the campaign two
  years ago.
- publishing a briefing containing the results of the Freedom of Information requests we sent to every hospital trust in the UK around Lynch Syndrome testing. It clearly highlighted the unsatisfactory and patchy nature of testing for this genetic condition which leads to a high risk of bowel cancer. In part due to our campaigning on this issue, we are delighted that the Royal College of Pathology has issued guidance and that NICE is also developing its own guidance which will be published in 2016.
- running another successful colorectal study day attended by 130 nurses and other clinical staff.
- winning a prestigious 2-year award from the Royal Society of Public Health for our volunteer health promotion programme.
- winning a BMA patient information award for our diet resource.
- the publication of new NICE referral guidance which included recommendations around people under 50 for the first time, as a result of our Never Too Young campaign.
- holding an excellent Parliamentary reception at Westminster attended by around 70 MPs and many other key stakeholders.
- increasing our income by 16.5% and continuing to build up our reserves so we have a firm foundation for 2016 and beyond.

The Board of Trustees and staff would like to offer grateful thanks to the charity's many clinical, academic and business advisors for their advice and practical help in 2015. We also want to especially thank our wonderful patient and fundraising supporters and volunteers without whom we would not exist and whose dedication is both humbling and inspiring.



### **Background**

In late 2014 we began a process of reviewing our strategic direction as a charity, as we are determined to make best use of our resources and focus on areas where we can add most value. After a thorough assessment, at the end of the first quarter of 2015, the Board made some key strategic decisions for the charity.

#### These were that:

- a) the charity would move into research, as a natural extension of our successful policy and campaigns activity. Whilst recognising that we currently don't have huge funds for grants yet, the advice we have been given by our expert medical and scientific advisors is that 'pump-priming' research through smaller grants in key areas, or becoming a partner in bigger research projects would fill a major gap in the sector, as there is currently no dedicated bowel cancer research charity. We are therefore well placed given our experience, skills, contacts and determination to make positive change for people affected by bowel cancer, to fill that gap.
- b) the charity will continue with our award winning health promotion and training activity as we believe this is essential to driving greater awareness in the public and health care professionals about the disease.
- c) the charity would, in the future, concentrate its services for patients and their families purely on providing clear information and sign posting about bowel cancer and its impact on to patients, their family and others affected by the disease. Along with promoting information about clinical trials, this will enable us to add value to the information and services of other charities, the NHS and private providers rather than duplicate their provision.

Our new strategic framework was developed and is shown on Page 3. The major change was to focus our strategic aims on around reducing our strategic aims to two key areas with policy and research cross cutting both areas and this report will use this new structure. Our mission remains unchanged.

Our values also remain unchanged and are central to who we are as an organisation. They inform our behaviours and decision making across the organisation including how we fundraise. We already had strong governance around fundraising but we have reviewed and strengthened this further in 2015.



#### **Bowel Cancer UK Strategic Plan 2015-2018**

#### Mission

Bowel Cancer UK is determined to save lives and improve the quality of life for all those affected by bowel cancer.

We achieve our mission through research, education and campaigns.

#### **Values and Operating Principles**

Bowel Cancer UK will always:

- ensure that the needs of all those affected by bowel cancer are at the heart of all we do;
- be informed by clinical and other healthcare professional expertise;
- work in partnerships that are beneficial to those affected by bowel cancer;
- act with honesty, transparency and integrity;
- strive for excellence, be innovative, independent and accountable for all we do;
- \* embrace diversity, treating everyone fairly, with understanding and respect.

# Strategic Aim 1 Champion early diagnosis of bowel cancer Improve access to best treatment and care for all those closely affected by bowel cancer

#### Organisational aim 1

Develop the charity's use of marketing and communications to increase our impact and reach

### Organisational aim 2

Develop a sustainable income base for the charity

#### Organisational aim 3

Develop the charity's infrastructure and resources to enable us to meet our mission



# Strategic Aim 1: Champion early diagnosis of bowel cancer

## In 2015 we said we would:

- train more volunteers to increase our reach across the country and develop targeted interventions to better reach high risk groups such as older people.
- seek to further strengthen our evaluation model, following up with attendees 3 and 6 months after seeing a presentation.
- conduct new research into the experiences of people with bowel cancer under the age
  of 50 to identify what has changed and make progress on improving access to
  surveillance screening for high risk groups.
- continue to press forward on our recommendations to improve capacity and access to endoscopy services in the UK.

### During 2015 we:

- took on new health promotion staff in Scotland and England with specialisms in health inequalities and Black and Minority Ethnicity (BME) groups, to increase our volunteer management capacity and enable our work in these areas.
- held 5 volunteer training days which included volunteers from East Anglia, Essex,
   Liverpool and the West Midlands, where we previously had no presence.
- continued to evaluate the health promotion volunteer talks at 3 months after the engagement and developed a model for 6 month follow up.
- reached 7,000 people throughout the UK directly with our volunteer talks programme.
- produced a film version of our volunteer talk for places we could not reach with our volunteers – used in the Hebrides, Wales and other areas with no volunteers.
- published the largest ever survey of younger bowel cancer patients. We heard from over 400 patients about their experiences. We published this in a report 'Leading the change for younger bowel cancer patients', alongside a new campaign film and a suite of infographics.
- worked with Colon Cancer Alliance and Colon Cancer Challenge Foundation in the US and Bowel Cancer Australia on their activities around Never Too Young to share information and best practice.
- published a briefing document on the extent of reflex testing for Lynch Syndrome in the UK. This was based on work using Freedom of Information requests, and was subsequently presented as a poster presentation at the Digestive Disorders Federation conference.



held a parliamentary reception in Westminster, attracting approximately 150 delegates,
 including around 70 parliamentarians with a theme of early diagnosis.

#### In 2016 we will:

- work with local public health teams, health boards, CCGs and nurses, delivering training to effectively reach those not taking part in screening and where awareness is low – e.g.
   BME groups, men, older people and people with learning disabilities.
- target our volunteer recruitment and talks to harder to reach groups such as BME groups and within areas of deprivation.
- extend the reach of our Bowel Cancer awareness month materials, for example targeting pharmacies in areas with low uptake of screening.
- release the results of the joint BodyShop research being conducted by Professor William Hamilton from the University of Exeter as part of our Never Too Young campaign. The aim of the research is to speed up referrals of people under 50 for diagnostic tests based on risk assessment criteria.
- continue our policy engagement to improve the identification and screening surveillance for people with genetic conditions which increase their risk of bowel cancer and will hold a summit in March 2016 with all relevant stakeholders to agree a way forward.
- continue to press forward on our recommendations to improve capacity and access to endoscopy services in the UK, working in partnership with the British Society of Gastroenterology.
- continue to proactively engage, including through participation in key committees, in improvements to the bowel cancer screening programme including implementation of the Faecal Immunochemical test across the UK.

# Strategic Aim 2: Improve access to best treatment and care for all those closely affected by bowel cancer

#### In 2014 we said we would:

- complete and launch (in April 2015) the information booklet for younger people along with new audio visual information for the website.
- start to develop an online information portal for patients and their families.
- deliver our annual clinical study day.



 publish two new policy reports on variations in resources in coloproctology and outcomes for patients with the Association of Coloproctology for Great Britain and Ireland (ACPGBI) on advanced bowel cancer.

### During 2015 we:

- developed and launched a new information booklet for younger people diagnosed with bowel cancer under the age of 50.
- produced a video specifically targeted at younger people; Alex's story highlights his personal experience of an active life with a stoma.
- started to develop a new online information portal for patients and their families.
- were re-certified to the Information Standard.
- held our fourth colorectal cancer study day in Leeds, attended by 130 health professionals working across primary and secondary care.
- were presented with a Self-Care award from the British Medical Association for our publication; Your Diet: Living with and beyond bowel cancer.
- won a British Medical Association award for our diet resource.
- in partnership with Penny Brohn Cancer Care we developed and delivered a Health and Well-being clinic and a "Living well with the impact of cancer" course in Aberdeen. As part of this pilot service, four facilitators based in Scotland were trained to deliver Living Well courses and will continue this work with Penny Brohn Cancer Care in the future.
- had the findings from our joint research with ACPGBI on resources in coloproctology presented at the Digestive Disorders Federation conference. The full report will be published in early 2016.
- joined the National Bowel Cancer Audit Clinical Advisory Group, and continued as joint secretariat to the NHS England Colorectal Cancer Clinical Reference Group.
- responded to six policy consultations, including submitting evidence to the Independent Cancer Strategy Task Force, NICE consultations on Lynch syndrome, faecal immunochemical testing in symptomatic patients, virtual chromo endoscopy, referral for suspected cancer guidelines and a UK National Screening Committee consultation on faecal immunochemical testing in screening programmes.
- published a joint report with Merck Serono, 'Testing the Gap', on biomarker testing in bowel, breast and lung cancer.
- began to scope and develop our first research strategy and committed to undertaking a research gap analysis in partnership with ACPGBI.

#### In 2016 we will:

deliver two colorectal study days in two different regions.



- launch our new information portal and develop new audio-visual material for the portal.
- develop an information resource for people at higher risk of bowel cancer focussing on genetics and family history.
- launch the joint research with the ACPGBI on resources in coloproctology.
- conduct and publish a landmark research project identifying the critical gaps in bowel cancer research.
- lead the public and patient communication outreach components of the 100,000 Genomes critical interpretation group for bowel cancer and support the public and patient communication on the stratified medicines consortium (S-CORT).
- publish a report on advanced bowel cancer as part of a new international campaign, which our Chief Executive, Deborah Alsina is co-chairing with the Chief Executive of Bowel Cancer Australia.

# Organisational aim 1: Develop the charity's use of marketing and communications to increase our impact and reach

### In 2014 we said we would:

- establish a 3 year marketing and communications strategy to set priorities.
- increase the organisation's media profile and coverage, including targeting the securing of celebrity supporters and broadening our range of media spokespeople.
- use our social media channels to grow our community of supporters.

### During 2015 we:

- refocused our organisational purpose to concentrate on research and campaigning.
   This will inform a new marketing and communications strategy.
- recruited a Head of Marketing and Communications to provide additional capacity to the team and to develop a strategy.
- reached 51.9 million people through our social media activity, an increase of 35% on 2014.
- achieved nearly 1,000 pieces of media coverage across national, regional and broadcast media
- commissioned the development of a brand refresh and new organisational website.

### In 2016 we will:

- launch our refreshed brand.
- launch our new organisational website.



 increase the organisation's social media and media coverage, proactively identifying opportunities across all channels and developing and building relationships with journalists.

# Organisational aim 2: Develop a sustainable income base for the charity

### In 2014 we said we would:

- explore potential for more opportunities to engage and motivate individual donors and community and events supporters to make committed gifts or to raise funds including by improving our supporter materials and developing our programme of bespoke community and challenge events.
- manage all existing relationships with major donors, trusts and statutory funders to secure on-going and multiyear support and develop and increase our base of supporters.
- secure and sustain high-value multi-year partnerships with companies.

### **During 2015:**

Bowel Cancer UK's fundraising activities raised £2m, the highest annual fundraising total ever generated by the charity. This represents a 16.5% increase on income from the previous year. We would like to express our gratitude to every company, trust, community group, event participant and individual giver who helped fund our work in 2015.

Highlights from our work this year include:

- increasing our base of community and events fundraisers with particular success in the number of own-place event participants who generously chose to support us.
- a very successful charity of the year partnership with law firm, Charles Russell Speechlys;
- taking part in the BGC charity trading day supported by our fantastic patrons Tom Hardy and Charlotte Riley and supporter Dermot O'Leary.

# In 2016 the fundraising team will:

- improve our fundraising materials and develop our programme of bespoke community and challenge events, to engage with and to motivate our supporters to donate regularly and raise funds in a wide range of ways so we can continue to deliver against our mission to save lives.
- manage all existing relationships with major donors, trusts and statutory funders to secure on-going and multiyear support and develop and increase our base of supporters.



secure and sustain high-value multi-year partnerships with companies.

# Organisational aim 3: Develop the charity's infrastructure and resources so we can meet our mission

#### In 2014 we said we would:

- complete the review of our strategy and priorities moving ahead.
- review all our HR policies and procedures and run another staff survey to identify any key issues that need to be addressed or what is working particularly well.
- review our financial management policies and procedures and ensure all budget holders are given finance training.

### During 2015 we:

- ran our second staff survey which was very useful. It showed high levels of staff satisfaction in the organisation but also gave us helpful recommendations on areas to improve in the future.
- reviewed our IT infrastructure and investigated the best options for the charity around server replacement and potential movement of some of our data to "The Cloud". This also included consideration of disaster recovery solutions.
- continued to review some of our key HR policies and procedures for which we will seek approval from Trustees in 2016.
- continued to develop our use of our Raiser's Edge database by looking at our use of data and ensuring our records are accurate and new records consistently recorded.

#### In 2016 we will:

- produce a fully integrated three year strategic plan.
- review all our HR policies and procedures and run another staff survey to identify any key issues that need to be addressed or what is working particularly well.
- review our financial management policies and procedures and ensure all budget holders are given finance training.

### Conclusion

2015 was another remarkable year for Bowel Cancer UK as we work to increase our impact and reach on behalf of people affected by the disease. However we are far from complacent, rather more determined than ever that in 2016 to grow the charity so that we



can do far more to ensure people are diagnosed as early as possible when treatment is most successful and gain access to the best treatment and care wherever they live in the UK.

#### **PUBLIC BENEFIT**

From 1<sup>st</sup> April 2008 the Charities Act 2006 requires all charities to meet the legal requirement that its aims are for the public benefit. The Charity Commission in its "Charities and Public Benefit" guidance requires that there are two key principles to be met in order to show that an organisation's aims are for the public benefit: first, there must be an identifiable benefit and secondly the benefit must be to the public or a section of the public. The Council of Management (which equates to the Board of Trustees and henceforth referred to as such) confirm they have regard to the Charity Commission's guidance on public benefit and consider each year how it meets the public benefit objectives outlined in Section 17 (5) of the Charities Act 2011. They are satisfied that Bowel Cancer UK meets the requirements and conforms to the Act's definition of a charity meeting all elements of the two key principles.

Our beneficiaries are at the heart of everything that we do as we believe this report fully demonstrates:

- We raise awareness of bowel cancer through our patient volunteer health promotion and outreach programme and work extensively with patients and their families in all our policy and campaigns activity;
- Our public health training programme ensures that key potential life-saving messages are appropriately cascaded across the UK;
- We work with patients, alongside policy makers, clinicians and scientists to ensure that the needs of those affected by bowel cancer are identified and addressed;
- We provide information to bowel cancer patients and their families, through developing and disseminating relevant information; and
- We provide a range of training and information materials for Health Care professionals to ensure they have access to latest research and experience to inform their practice.

## REGULATORY AND ADMINSTRATIVE DETAILS

# **Regulatory Compliance Statements**

Bowel Cancer UK is registered as a company limited by guarantee no. 3409832 and has a charity no. 1071038 in England and Wales and SC040914 in Scotland. The principal office address is Willcox House, 140-148 Borough High Street London SE1 1LB, it is also the registered office address.



The Trustees are also the Directors of the Charitable Company for the purposes of the Companies Act. The Trustees in presenting their annual report and financial statements for the year ended 31<sup>st</sup> December 2015 for the Charitable Company confirm that they comply with the current statutory requirements, the requirements of the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) — (Charities SORP (FRS 102)).

#### Who we are

Established in 1987, Bowel Cancer UK is determined to save lives and improve the quality of life of all those affected by bowel cancer.

The main activities of the organisation include:

- educating patients, the public and healthcare professionals about the disease
- enabling and supporting research
- campaigning for best treatment and care for all

For more information visit our website www.bowelcanceruk.org.uk



#### Where we are

The London Office (Principal & Registered office)

Willcox House

140-148 Borough High Street

London

SE1 1LB

Tel: 020 7940 1760

Fax: 020 7940 1761

Email: <a href="mailto:admin@bowelcanceruk.org.uk">admin@bowelcanceruk.org.uk</a> Website: <a href="mailto:www.bowelcanceruk.org.uk">www.bowelcanceruk.org.uk</a> The Scottish Office

20 Queen Street

Edinburgh

EH2 1JX

Tel: 0131 225 5333

### **Council of Management (Board of Trustees)**

The following individuals acted as Trustees throughout the year:

Peter Sedgwick (Chair - member of FRC)

Stephen Gibson (Vice Chair)

Linda Clemett (Treasurer – member of FRC)

Richard Anderson

Mark Hodgson

Dennis Horner (member of FRC)

Christina Dolan Lakin

Jerry Luckett (Resigned 13 October 2015)

Alastair Macpherson (Resigned 30 January 2015)

John Schofield

Michelle Scott (member of FRC)

#### **Chief Executive and Senior Management Team**

Chief Executive (member of FRC)

Deborah Alsina

Director of Fundraising (member of FRC)

Luke Squires

Director of Finance and Resources and

Company Secretary (member of FRC)

Simon Hawkins



## Member of our Medical Advisory Board are:

Richard Adams, Consultant Clinical Oncologist, Cardiff University and Velindre Cancer Centre Annie Anderson, Professor of Food Choice, University of Dundee

Jervoise Andreyev, Consultant Gastroenterologist in Pelvic Radiation Disease, Royal Marsden Hospital

Wendy Atkin, Professor of Gastrointestinal Epidemiology, Imperial College London

Tom Cecil, Consultant Colorectal and General Surgeon, Basingstoke and North Hampshire NHS Foundation Trust

Mark Coleman, Consultant Surgeon, Plymouth, Lead Clinician, Lapco National Training Programme for Laparoscopic Colorectal Surgery

Stephen Fenwick, Consultant Hepatobiliary Surgeon, University Hospital Aintree

Nicola Fearnhead, Consultant Surgeon, Addenbrookes Hospital; Chair, ACPGBI Research and Audit Committee

Rob Glynne-Jones, Consultant Clinical Oncologist, Mount Vernon Cancer Centre (Chair)

Willie Hamilton, Professor of Primary Care Diagnostics, University of Exeter

Tim Iveson, Cancer Relief Macmillan Fund Consultant in Medical Oncology, Southampton University Hospitals NHS Trust

Michael Machesney, Pathway Director for Colorectal Cancer, London Cancer, UCL Partners

Kevin Monahan, Consultant gastroenterologist, West Middlesex University Hospital

Eva Morris, Principle Research Fellow, Leeds University

Dion Morton, Professor of Surgery, University of Birmingham

Christine Norton, Nurse Consultant, St Mark's Hospital

Greg Rubin, Professor of General Practice and Primary Care, Durham University

John Schofield, Cellular Consultant Pathologist, Maidstone; South East Coast Pathology Lead, Bowel Cancer Screening Programme

John Stebbing, Consultant Surgeon, Royal Surrey County Hospital NHS Foundation Trust; Clinical Director, Surrey Bowel Cancer Screening Centre, Chair, UK Joint Advisory Group on GI Endoscopy (the JAG)

Bob Steele, Professor of Surgery and Head of Department, University of Dundee

Mark Taylor, Consultant Hepatobiliary and Pancreatic Surgeon, Belfast Health & Social Care Trust

Professor Ian Tomlinson, Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics

Richard Wilson, Clinical Director, Northern Ireland Cancer Trials Centre and Network, Queen's University Belfast

We are also very fortunate to have extensive support from many other fantastic senior clinicians and scientists across the UK, who are too many to mention individually, and for which we are truly grateful.



## **Auditors, Bankers and Solicitors**

**Auditors** 

Crowe Clark Whitehill LLP

**Aquis House** 

49-51 Blagrave Street

Reading RG1 1PL

**Bankers** 

The Bank of Scotland

St James's Gate

14/16 Cockspur Street

London SW1Y 5BL

**Solicitors** 

Lamb Brooks LLP

Victoria House,

39 Winchester Street,

Basingstoke, Hampshire RG21 7EQ

### STRUCTURE, GOVERNANCE AND MANAGEMENT

## **Governing Document and Constitution**

Bowel Cancer UK is registered as a company limited by guarantee (without share capital) and as a charity its governing instrument is its Memorandum and Articles incorporated 25 July 1997 as amended by special resolutions dated 14 June 2007 and 23 December 2011. All the Members of the Charitable Company are Trustees and undertake to contribute to its assets in the event of it being wound up while s/he is a member, such amount as may be required not exceeding £1. All the Trustees are also Directors of the Charitable Company for the purposes of the Companies Act.

## Trustees Appointment, Recruitment, Training and Induction

All Trustees are unremunerated and are voluntary. Trustees are appointed by resolution of the Trustees. Each Annual General Meeting one third of the Trustees shall be subject to retirement by rotation, but may offer themselves for re-election. No person other than a Trustee retiring by rotation shall be appointed as a Trustee at any general meeting of Trustees unless he or she is recommended by the Trustees. No Trustee may serve more than 7 years. After 7 years Trustees are not eligible for election until 3 years have elapsed.



Each new Trustee is provided with a detailed information pack upon appointment. This covers an introduction to fellow Trustees; details of the leadership team and staff accompanied by an organisation chart; Articles of Association; the history of the organisation; its objectives and policies; its work and products; recent Trustees and Sub-Committee minutes of meetings; the latest audited Trustees Report and Financial Statements; information on the role and responsibilities of a Trustee.

Training of Trustees will be given on new legislative issues affecting charity Trustees and directors as needed.

# **Organisation Structure and Decision-Making**

A voluntary Board of Trustees is responsible for the overall management and direction of the Charitable Company. The Board meets four times a year. A Senior Management Team meets monthly and reports to the Trustees. The members of the group are shown on page 12.

Authority on financial, personnel and regulatory matters has been delegated to a Finance and Resources Sub-Committee (FRC) which review management accounts, and the progress of the annual audit, as well as personnel and recruitment policies and compliance with the regulatory environment within which the organisation operates. The FRC meets six times a year with its meetings being staged between main Trustee meetings. It makes recommendations both to the Senior Management Team and to the main Board of Trustees. Membership currently comprises of the Chair of Trustees, the Treasurer and two other Trustees, the Chief Executive, Director of Fundraising and the Director of Finance and Resources.

## **Directors/Trustees retiring**

The Directors retiring by rotation were Richard Anderson, Stephen Gibson and Mark Hodgson, all of whom were eligible for re-election and who were reappointed.

# Pay policy for senior staff

The directors consider the board of directors, who are the Charity's trustees, and the senior management team comprise the key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis. All directors give of their time freely and no director received remuneration in the year. Details of directors' expenses are disclosed in note 6 to the accounts and related party transactions in note 13.



The Chair of the Board will as necessary make a proposal on the remuneration of the CEO to the FRC for its agreement. The CEO makes recommendations as necessary on remuneration levels for any staff earning £50k or more to the FRC for its approval. The Board is notified of decisions.

The charity is planning to introduce a pay and remuneration strategy in 2016 which will seek trustee approval in March 2016.

#### **Risk and Uncertainties**

Achievement of our aims and objectives entails taking risks. The Trustees are satisfied that appropriate internal control systems and risk management processes are in place. They consider that the following framework provides the Bowel Cancer UK with adequate measures to reduce the impact of identified risks:

- The Finance and Resources Sub-Committee reviews risk and internal controls, approves the annual risk-register, and receives regular progress reports on key risks.
- Senior management reviews key strategic and operational risks on a regular basis. They
  consider progress on mitigating actions, new and emerging risks, and opportunities.
- Board sub-committees and management groups help identify, evaluate and manage risks relating to fundraising, governance, health and safety and remuneration.

The most significant risks to the Bowel Cancer UK include income generation and cash flow management, reputation, health and safety of staff and volunteers, operational management information, IT infrastructure, staff retention and development.

#### **FINANCIAL REVIEW**

The results for the year ended 31 December 2015 are set out on page 22 of the financial statements.

Total incoming resources for the year increased to £2,013,684 (2014: £1,729,104) as a result of the amazing efforts of our many volunteers who raised money for us doing runs, treks and holding events in their community and fantastic support from corporate supporters and many different trusts and foundations. In particular in 2015 we can report:

- A 17.5% increase in community fundraising and events from £1,001,265 in 2014 to £1,176,598 in 2015;
- A 49% increase in corporate donations from £160,432 in 2014 to £239,441 in 2015;
   and
- A 5% increase in individual donations from £185,933 in 2014 to £195,143 in 2015.

Total resources expended for the year decreased by 2% from £1,693,428 in 2014 to £1,656,570. Expenditure was tightly monitored and controlled throughout the year and we



continue to keep governance and support costs to the minimum levels necessary to ensure the effective running of the charity.

The use of restricted funds has been maximised and this coupled with our most successful year ever for fundraised income has seen our unrestricted reserves increase by £286,746 to stand at £497,287 at the end of the year. Our overall surplus for the year of £357,114, compares to a much smaller surplus of £35,676 in 2014. The Charity's spare cash balances have been invested in interest bearing accounts.

The Balance Sheet on page 23 reflects the activities in the year. The increase in current assets from £395,437 in 2014 to £756,917 in 2015 reflects an increase in cash following the year's strong financial performance coupled with the inclusion of a debtor for a material legacy where probate had been granted during the year. Both fixed assets and creditors are lower year on year.

Key Performance Indicators for the year are:

- The fundraising ratio has increased by 10% to stand at £2.53 for every £1 spent in the year. The plan is for this to continue to improve in 2016 and future years.
- Support costs remain on target (below 15%) at 14% for the year (12% in 2014).
- Unrestricted reserves have risen from 1.5 month's running costs in 2014 to 3.6 month's running costs in 2015, achieving the Trustees' short term target of 3 months. The Trustees aim to continue to rebuild the reserves to the level they consider necessary for the future stability of the charity.

#### RESERVES

The Board of Trustees recommend that to allow the Charity to be managed efficiently, an unrestricted reserve equivalent to at least three months operating expenditure (with a longer term aim of six months) should be built up. The Trustees believe that this is the minimum level of reserves required to ensure the operating efficiency of the charity and to provide some protection to the organisation, its charitable programmes and to provide time to adjust to changing financial circumstances.

The Charity now has free reserves of £446,925 (2014: £137,293) which equates to 3.2 months running costs. Over the next few years efforts will continue to be made to accumulate reserves whilst still facilitating and expanding Bowel Cancer UK's services, public awareness and policy campaigns.



Designated funds are amounts identified by the Trustees for a particular project or use. The Trustees have also reduced the amount in the designated fund for fixed assets to £50,362, to reflect the net book value of the fixed assets.

Restricted funds are detailed in Note 11 to the financial statements.

Statement of Trustees' responsibilities

The Trustees (who are also directors of Bowel Cancer UK for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



### **Provision of information to auditors**

In so far as the Trustees are aware:

- There is no information of which the charitable company's auditors are unaware; and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

#### Staff and Volunteers

The Board of Trustees wish to record their thanks and appreciation to all staff and volunteers for their devoted work, often beyond the call of duty to ensure that the charity continues to meet its mission.

#### **Auditors**

The Company's auditors, Crowe Clark Whitehill LLP are willing to continue in office. A resolution proposing their re-appointment will be considered at the next Annual General Meeting.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

This report was approved by the Council of Management / Board of Trustees on 22 March 2016 and signed on their behalf by

Linda Clemett, Member of Council

# BOWEL CANCER UK INDEPENDENT AUDITOR'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2015



# Independent Auditors' Report to the Trustees and Members of Bowel Cancer UK

We have audited the financial statements of Bowel Cancer UK for the year ended 31 December 2015 set out on pages 22 to 41. The financial reporting framework that has been applied in their preparation is applicable law, United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charitable company's trustees, as a body, in accordance with section 44(1c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's trustees and members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

## Respective responsibilities of trustees and auditor

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purpose of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditor under section 44(1c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

# Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently

# BOWEL CANCER UK INDEPENDENT AUDITOR'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2015



materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

# Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the charity's state of affairs as at 31 December 2015 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

# Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

# Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns;
   or
- certain disclosures of Trustees' remuneration specified by law are not made; or we have not received all the information and explanations we require for our audit; or
- if the small companies regime has been used the trustees were not entitled to prepare
  the financial statements in accordance with the small companies regime and take
  advantage of the small companies exemption in preparing the trustees annual report.

J. Jayce

Janette Joyce

Senior Statutory Auditor, for and on behalf of Crowe Clark Whitehill LLP

Statutory Auditor

Reading

Date: 22 March 2016

Crowe Clark Whitehill LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.



# Statement of Financial Activities For the year ended 31st December 2015

(incorporating the income and expenditure account)

(incorporating the income and expen		Unrestricted	Restricted	2015	2014
	Note	Funds	Funds	Total	Total
		£	£	£	£
INCOME					
Donations and legacies	2	536,946	287,279	824,225	716,062
Other trading activities	2	1,125,597	51,001	1,176,598	1,001,265
Income from investments		1,562		1,562	388
Income from charitable activities	3	3,799	7,500	11,299	11,389
Total income	9	1,667,904	345,780	2,013,684	1,729,104
EXPENDITURE					8
Expenditure on raising funds	4	794,904	8	794,904	758,568
Expenditure on charitable activities	4	586,254	275,412	861,666	934,860
Total expenditure	9	1,381,158	275,412	1,656,570	1,693,428
Net income	5	286,746	70,368	357,114	35,676
Transfers between funds		•	8	<u>.</u>	¥
Net movement in funds		286,746	70,368	357,114	35,676
Total funds brought forward		210,541	67,398	277,939	242,263
Total funds carried forward	11	497,287	137,766	635,053	277,939

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 25-41 form part of these financial statements.

# Balance Sheet as at 31<sup>st</sup> December 2015 Company number 3409832 (England and Wales)

Ь	owel cerk
	SOVO
	lives

			11.4
	Note	2015	2014
		£	£
Fixed assets			
Tangible assets	7	43,496	73,248
Intangible assets		6,866	
		50,362	73,248
Current assets			
Debtors and prepayments	8	300,112	139,925
Cash at bank and in hand		456,805	255,512
		756,917	395,437
Creditors: amounts falling due within one year	9	(148,226)	(166,746)
Net current assets		608,691	228,691
Provisions: amounts due in more than one year	10	(24,000)	(24,000)
NET ASSETS		635,053	277,939
Funds			
Unrestricted funds			
Designated		50,362	73,248
General funds		446,925	137,293
	11	497,287	210,541
Restricted funds	11	137,766	67,398
TOTAL FUNDS	12	635,053	277,939

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 22 March 2016 by

Linda Clement

Linda Clemett

Member of Council

The notes on pages 25-41 form part of these financial statements.



# Statement of Cash Flows For the year ended 31<sup>st</sup> December 2015

Cash used in operating activities  Cash flows from investing activities: Interest income Purchase of fixed assets  Change in cash and cash equivalents at the end of the year  Cash and cash equivalents at beginning of the year Movement  Total cash and cash equivalents at end of the year  Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds Depreciation Increase) in debtors Description Descriptio	For the year ended 32 December 2020	2015	2014
Cash flows from investing activities: Interest income Purchase of fixed assets  Change in cash and cash equivalents at the end of the year  Cash and cash equivalents at beginning of the year Movement  Total cash and cash equivalents at end of the year  Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds Depreciation (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets Interest income  Net cash used in operating activities  Cash in hand Notice deposits (less than 3 months)  371,134 255,512		£	£
Interest income Purchase of fixed assets  Change in cash and cash equivalents at the end of the year  Cash and cash equivalents at beginning of the year Movement  Total cash and cash equivalents at end of the year  Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds Depreciation (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets Interest income  Net cash used in operating activities  Net cash used in operating activities  Net cash in hand Notice deposits (less than 3 months)  371,134 255,512  388  288,912) (23,658)  201,293 (23,658)  279,170 201,293 (23,658)  279,170 201,293 (23,658)  255,512  279,170 201,293 (21,658) 21,293 (21,658) 21,293 (21,658) 21,293 (21,	Cash used in operating activities	208,643	4,463
Purchase of fixed assets  Change in cash and cash equivalents at the end of the year  Cash and cash equivalents at beginning of the year  Movement  Total cash and cash equivalents at end of the year  Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds  Net movement in funds  (lncrease) in debtors (lncrease) in creditors (locrease) in creditors (loss on disposal of fixed assets Interest income  Net cash used in operating activities  Net cash used in operating activities  Net cash used in operating activities  Cash in hand Notice deposits (less than 3 months)  85,671	Cash flows from investing activities:	4 500	200
Change in cash and cash equivalents at the end of the year  Cash and cash equivalents at beginning of the year  Movement  Total cash and cash equivalents at end of the year  Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds  Depreciation  (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets Interest income  Net cash used in operating activities  Cash in hand Notice deposits (less than 3 months)  371,134  255,512	Interest income		
Year       201,293       (23,658)         Cash and cash equivalents at beginning of the year       255,512       279,170         Movement       201,293       (23,658)         Total cash and cash equivalents at end of the year       456,805       255,512         Reconciliation of net movement in funds to net cash flow from operating activities       357,114       35,676         Net movement in funds       31,453       27,802         (Increase) in debtors       (160,187)       (57,712         (Decrease) in creditors       (18,520)       (1,056,         Loss on disposal of fixed assets       345       141         Interest income       (1,562)       (388,         Net cash used in operating activities       208,643       4,463         Analysis of cash and cash equivalents         Cash in hand       371,134       255,512         Notice deposits (less than 3 months)       85,671	Purchase of fixed assets	(8,912)	(28,509)
Movement Total cash and cash equivalents at beginning of the year  Movement Total cash and cash equivalents at end of the year  Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds Depreciation (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets Interest income  Net cash used in operating activities  Net cash used in operating activities  Analysis of cash and cash equivalents  Cash in hand Notice deposits (less than 3 months)  201,293 255,512 201,293		201,293	(23,658)
Movement         201,293         (23,658)           Total cash and cash equivalents at end of the year         456,805         255,512           Reconciliation of net movement in funds to net cash flow from operating activities         357,114         35,676           Net movement in funds         31,453         27,802           (Increase) in debtors         (160,187)         (57,712           (Decrease) in creditors         (18,520)         (1,056)           Loss on disposal of fixed assets         345         141           Interest income         (1,562)         (388)           Net cash used in operating activities         208,643         4,463           Analysis of cash and cash equivalents         371,134         255,512           Cash in hand         371,134         255,512           Notice deposits (less than 3 months)         85,671	Cook and each aguivalents at beginning of the year	255,512	279,170
Reconciliation of net movement in funds to net cash flow from operating activities  Net movement in funds Depreciation (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets Interest income  Net cash used in operating activities  Cash in hand Notice deposits (less than 3 months)  Associated where the year 456,805  255,512  255,512  255,512  255,512  255,512  255,512  255,512  255,512  255,512  255,512  255,512			(23,658)
Net movement in funds Depreciation (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets Interest income  Net cash used in operating activities  Cash in hand Notice deposits (less than 3 months)  Net movement in funds 357,114 35,676 (160,187) (160,187) (160,187) (18,520) (1,056) (1,056) (1,562) (388)  208,643  4,463		456,805	255,512
Net cash used in operating activities  Analysis of cash and cash equivalents  Cash in hand Notice deposits (less than 3 months)  208,643  4,463  371,134  255,512	Net movement in funds Depreciation (Increase) in debtors (Decrease) in creditors Loss on disposal of fixed assets	31,453 (160,187) (18,520) 345	35,676 27,802 (57,712) (1,056) 141 (388)
Analysis of cash and cash equivalents  Cash in hand  Notice deposits (less than 3 months)  371,134  255,512			4,463
Notice deposits (less than 3 months)  85,671			
Notice deposits (less than 3 months) 85,671	Cash in hand	371,134	255,512
		85,671	- 2
		<u> </u>	(#
Total cash and cash equivalents at end of the year 456,805 255,512	Total cash and cash equivalents at end of the year	456,805	255,512

The notes on pages 25-41 form part of these financial statements

# 1. Accounting policies

#### **Basis of preparation** 1.1

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Bowel Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note (s).

Bowel Cancer UK is registered as a company limited by guarantee (without share capital) incorporated in the UK with its registered office at Willcox House, 140-148 Borough High Street, London SE1 1LB.

The Trustees consider that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future and for this reason they continue to adopt the going concern basis in preparing the annual financial statements.

#### Company status 1.2

The Charity is a company limited by guarantee. The guarantors are the members of Council named on page 12. The liability in respect of the guarantee, as set out in the memorandum, is limited to £1 per member of the company.

#### Income 1.3

Income is accounted for on an accruals basis, with the exception of donations which are accounted for when received.

Grants are credited as income in the year in which they are receivable. Grants are recognised as receivable when all conditions for receipt have been complied with. Where donor-imposed restrictions apply to the timing of the related expenditure as a precondition of it use, the grant is treated as deferred income until those restrictions are met. Grants received for specific purposes are accounted for as restricted funds.

Legacy income is included in the financial statements when the charity is satisfied that the conditions of recognition have been met. Pecuniary legacies are accounted for when notified. Residuary legacies are accounted for when notification of impending distribution is received and / or receipt occurs. Residuary legacies subject to a life interest held by another party are not included in income until the conditions associated with payment have been fulfilled.



Donated services totalling of £54,211 are included as a gift in kind and an expense and are included at their estimated value to the charity where this is reasonably quantifiable and measurable. In accordance with the Charities SORP (FRS 102), the general time of volunteers is not recognised. Refer to the trustees' annual report for more information about their contribution.

### 1.4 Expenditure

All expenditure is charged on an accruals basis and is allocated between:

- expenditure incurred directly on charitable activities;
- expenditure on raising funds;

Wherever possible, costs are allocated directly to the appropriate activity.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the charity's activities. These costs have been allocated to the charitable activities on the basis of staff numbers.

### 1.5 Fund accounting

General funds are available for use at the discretion of the Council of Management in furtherance of the general objectives of the Charity.

Designated funds comprise unrestricted funds that have been put aside at the discretion of the Trustees for particular purposes (see note 11). Each Designated fund is applied by the Board of Trustees on the recommendation of the Finance & Resources Sub-Committee.

Restricted funds are funds subject to specific restriction imposed by donors or by the purpose of appeals. The purpose and use of the restricted funds is set out in the notes to the financial statements (see note 11).

All income and expenditure is shown in the Statement of Financial Activities.

# 1.6 Reconciliation with previous Generally Accepted Accounting Practice

In preparing the accounts, the trustees have considered whether in applying the accounting policies required by FRS 102 and the Charities SORP FRS 102 the restatement of comparative items was required. In their estimation, the impact of transitioning is not material to the financial statements and therefore the restatement of comparative items is not required. The transition date was 1 January 2014.

# bould save lives

# Notes to the Financial Statements For the year ended 31st December 2015

# 1.7 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost including any incidental expenses of acquisition.

Assets with a cost in excess of £500 intended to be of ongoing use to Bowel Cancer UK in carrying out its activities are capitalised as fixed assets.

Depreciation is provided on all tangible fixed assets at rates calculated to spread each asset's cost, less its estimated residual value at current market prices, evenly over its expected useful economic life, which for each class of asset is initially assessed as averaging:

Computer equipment - over 4 years Fixture & Fittings – over 5 years Office Refurbishment – over 3 years

# 1.8 Intangible fixed assets

Website development costs have been capitalised within intangible assets as they can be identified with a specific project anticipated to produce future benefits. Once brought into use they will be amortised on the straight line basis over the 4 years anticipated life of the benefits arising from the completed project.

# 1.9 Debtors and prepayments

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

## 1.10 Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account.

## 1.11 Operating leases

The charity classifies the lease of offices in London and Edinburgh and the London office franking machine as operating leases; the title to the equipment remains with the lessor and the equipment is replaced every 5 years which is in line with its economic life.

Rentals payable under operating leases are charged to the Statement of Financial Activities on a straight line basis over the life of the lease.

### 1.12 Pension costs

The company operates a defined contribution group personal pension scheme. The charge in the SOFA is the amount of contributions payable to the pension scheme in respect of the accounting year.



### 1.13 Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

### 1.14 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

# 1.15 Critical accounting judgements and key sources of estimation uncertainty

Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are as follows:

Dilapidation provision – the charity has provided for its possible liability in relation to its leasehold property which has been estimated, as disclosed in Note 10.

Residuary legacies – the charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

The estimates and underlying assumptions are reviewed on an on-going basis. In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets and liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.



# 2. Income from generated funds

	2015	2014
	£	£
Donations and legacies		
Donations from individuals	195,143	185,933
Legacies	160,820	123,166
General grants	228,821	246,531
Corporate donations	239,441	160,432
	824,225	716,062
Other trading activities	394,079	386,103
Runs		
Treks and challenges	233,344	215,309
Community fundraising	512,141	368,454
Other special events	8,818	27,786
Rental income	28,216	3,613
	1,176,598	1,001,265
3. Income from charitable activities		
	2015	2014
	£	£
Training	11,299	11,389
Truning.		11,389



# 4. Resources expended

	Direct o	osts	Support	costs	Total	Total
	Staff	Other	Staff	Other	2015	2014
	£	£	£	£	£	£
Expenditure on raising f	unds					
Costs of generating voluntary income	391,498	289,847	73,282	40,277	794,904	758,568
	391,498	289,847	73,282	40,277	794,904	758,568
Expenditure on charital activities	ole					
Awareness & Direct Services	251,532	215,552	51,320	28,207	546,611	687,196
Communications and Campaigning	154,210	120,921	25,764	14,160	315,055	247,664
	405,742	336,473	77,084	42,367	861,666	934,860
Total costs	797,240	626,320	150,366	82,644	1,656,570	1,693,428

Support costs have been allocated on the basis of staff numbers employed in each area of activity.

Total costs above include the following governance costs:

Bank charges	9	826	5#	2,354	( <del>=</del> )	3,288
Legal and Professional		1020	¥.	35		72
Audit and Accountancy		122	( <b>2</b> )	11,406	##B	11,333
Addit and Accountancy				13,795	-	14,621



# 5. Net incoming resources is stated after charging:

	2015 £	2014 £
Depreciation Operating lease payments	31,453 87,836	27,802 89,311
Auditors' remuneration:  - Audit fee for the current period  - Non Audit fee for the current period	8,750 755	8,750 695
6. Staff costs	2015 £	2014 £
Wages and salaries Social security costs Pension Contributions	844,513 84,426 18,667 947,606	902,207 88,090 13,370 1,003,667



# 6. Staff costs (Continued)

The number of employees whose emoluments exceeded £60,000 fell within the following ranges:

	2015 Number	2014 Number
£60,000 - £70,000	*	1
£70,001 - £80,000	1	
170,001 100,000	1	1

Pension Contributions of £2,880 (2014:£2,840) were paid in respect of the higher paid individual.

The charity contributes to group personal pension schemes (defined contribution) for all participating employees. The assets of the schemes are held separately from those of the charity in independently administered funds. The pension charge represents contributions payable by the charity to the fund. Pension contributions outstanding at 31 December 2015 amounted to £nil (2014: £288).

The key management personnel of the charity comprise the trustees, the Chief Executive, Director of External Affairs, Director of Finance and Resources and Director of Fundraising. The total employee benefits of the key management personnel of the charity were £205,558 (2014 -£198,219).

The average number of staff analysed by function was:

The average number of staff analyses	2015 Number	2015 FTE	2014 Number	2014 FTE
Eundraising	10	10	11	11
Fundraising Awareness & Direct Services Communications and Campaigning Central Support	8	7	9	7
	4	3	5	5
	4	4	4	4
	26	24	29	27

#### **Trustees**

None of the trustees received, nor waived, any emoluments during the year (2014: £nil). One of the trustees received reimbursed travel expenses totalling £255 during the year (2014: £nil). Eight of the trustees made a donation to the charity in aggregate of £1,547 (2014: 9 trustees with donations in aggregate of £10,423).



## 7. Tangible fixed assets

7. Tangine fixed assets	Office Refurbishment £	Fixture & Fittings £	Computer Equipment £	Total £
Cost At 1 January 2015 Additions Disposals At 31 December 2015	46,887	23,750 1,241 	60,187 805 (690) 60,302	130,824 2,046 (690) 132,180
Depreciation At 1 January 2015 Charge for the period Disposals	18,896 15,473	7,168 4,857	31,512 11,123 (345)	57,576 31,453 <u>(345)</u>
At <b>31 December 2015</b>	<u>34,369</u>	12,025	42,290	<u>88,684</u>
Net book value as at 31 December 2015	12,518	12,966	18,012	43,496
Net book value as at 31 December 2014	27,991	16,582	28,675	73,248

All fixed assets are used for charitable purposes.



# 8. Debtors and Prepayments

	2015 £	2014 £
Legacy Debtor Other Debtors Prepayments and accrued income	141,000 22,013 137,099	20,013 119,912
Tropaye.	300,112	<u>139,925</u>

### 9. Creditors

	2015 £	2014 £
Trade creditors Accruals Taxes and social security costs Deferred Income Other creditors	46,203 57,408 24,806 12,642 	78,028 49,689 21,021 10,300 7,708

Deferred income relates to restricted income due to be repaid to funders following the completion of projects.

of projects.	2015 £	2014 £
Deferred income at 1 January Income deferred in the current year Amounts released from previous reporting periods Deferred income at 31 December	10,300 2,642 (300) 12,642	22,500 10,300 (22,500) 10,300



### 10. Provisions

	Property provision 2015 £	Property provision 2014 £
At 1 January 2015	24,000	24,000
Amounts reversed Amounts introduced	7 <u></u>	
At 31 December 2015	24,000	24,000

The dilapidation provision relates to amounts provided to reflect the cost of restoring the condition of the leased property in accordance with the lease agreement.

# 11. Statement of funds

	Balance 1 January 2015 £	Income £	Expenditure £	Transfers Between Funds	Balance 31 December 2015 £
<b>Total Designated</b>					
funds: Fixed Assets	73,248			(22,886)	50,362
Total General Funds	137,293	1,667,904	(1,381,158)	22,886	446,925
Total Unrestricted funds	210,541	1,667,904	(1,381,158)		497,287

## **Designated funds**

Designated funds are amounts identified by the Trustees for a particular project or use.

Designated funds of £50,362 (2014: £73,248) have been set aside from the charity's unrestricted funds by the trustees to reflect the net book value of the fixed assets.



# 11. Statement of funds (continued)

	1 January			3	31 December
	2015	Income	Expenditure	Transfers	2015
	£	£	£	£	£
Restricted Funds:					
Awareness NI	194	6,000	(6,000)	2.5	((*)
Awareness Scotland	5,273	35,750	(25,366)	3,750	19,407
Printing	174	7,242	(7,416)	•	-
Information & Support	6,744	2	(6,744)	-	
Communications Officer	11,445	34,840	(38,376)	3,00	7,909
Diet Resource	1,000	6,488			7,488
Young Peoples Service	16,729	22,776	(39,505)	<b>€</b>	4
ACPGBI	7,629	25	(7,629)	1983	
Penny Brohn	17,854	4,645	(18,749)	(3,750)	•
Colorectal Cancer Study Days	(2)	29,250	(29,250)	÷	2
Awareness Staff	-	5,471	(5,471)	(4)	*
Awareness	2	32,850	(28,531)	1.00	4,319
General Patient Services	550	13,850	(10,500)	1.50	3,900
General Work in Scotland	7.0	26,270	(26,270)	-	¥
General Work in Northern Ireland	₩	58,862	(23,158)	•	35,704
Website Development	-	6,833	2,50	Ēf.	6,833
Research	8	31,386	(1,903)	2	29,483
General Work in Wales	2	6,866	*	*	6,866
Patient Information Videos	-	5,000		-	5,000
Get Personal		11,401	(544)		10,857
<b>Total Restricted funds</b>	67,398	345,780	(275,412)	·	137,766

Page 36



## 11. Statement of funds (continued)

#### **Restricted funds**

Restricted funds are where the donor has imposed restrictions on the use of the funds.

#### **Awareness NI**

For recruiting, training and supporting of Bowel Cancer Awareness volunteers in Northern Ireland.

#### **Awareness Scotland**

This fund is being used to recruit, train and support Bowel Cancer Awareness volunteers in Scotland.

#### **Printing**

This funding was to develop and print a range of patient resource materials.

### **Information & Support**

Funding was brought forward from 2014 and was used to develop our strategy to improve the efficiency of our information & support services, to expand our range of patient materials and to design and pilot specific support services for younger people.

#### **Communications Officer**

Additional funding was secured in the year to increase our staff resource with our communications and PR team.

#### **Diet Resource**

Funding for this project has been received to reprint a further 2,000 copies of the pack following the success of the first print run.

#### Young People's Service

Funding has been received to develop a new programme of information services for younger people (those under 50) with bowel cancer.

#### **ACPGBI**

Funding was brought forward from 2014 and has been used towards the research project 'Patient Outcomes in Coloproctology and their Correlation with Resources for Treatment' run in partnership with the Association of Coloproctology of Great Britain and Ireland.

### **Penny Brohn**

Funding has been received towards a partnership project with Penny Brohn Cancer Care which will deliver 'Living Well with the impact of bowel cancer' support services to bowel cancer survivors in Scotland.

#### **Colorectal Cancer Study Days**

Funding has been received to deliver a study day designed for practitioners caring for people affected by colorectal cancer in primary and secondary care settings. This is an essential update in early detection, prevention, screening, treatment and survivorship. The study day supports the professional development of health professionals across primary and secondary care and promotes best practice to improve standards of care.



## 11. Statement of funds (continued)

#### **Awareness Staff**

Funding has been received towards the staff costs of running our health promotion and awareness raising activities in England.

#### **Awareness**

Funding has been received to fund the recruitment, training and support of Bowel Cancer UK's Health Promotion Volunteers in England.

## **General Patient Services**

Funding has been received to sustain and support Bowel Cancer UK's programme of information services for bowel cancer patients, their families and carers.

### **General Work in Scotland**

Funding has been received to sustain and support Bowel Cancer UK's programme of health promotion, patient support, and policy work in Scotland.

## General Work in Northern Ireland

Funding has been received to sustain and support Bowel Cancer UK's programme of health promotion, patient support, and policy work in Northern Ireland.

## **Website Development**

Funding has been received as contributions towards the cost of on-going improvements to the Charity's website.

#### Research

Funding has been received to support the Critical Gaps in bowel cancer research project.

#### **General Work in Wales**

Funding has been received to introduce Bowel Cancer UK's programme of health promotion, patient support, and policy work in Wales.

#### **Patient Information Videos**

Funding has been received to help produce some patient information videos.

### **Get Personal**

Funding has been received to support a new international campaign on advanced bowel cancer. Bowel Cancer UK co-chair's this campaign with Bowel Cancer Australia.

#### Intra-Fund transfers

Intra-Fund transfers in the year amounted to £26,636 (2014: £1,150).



12. Analysis of net assets	between	funds
----------------------------	---------	-------

12. Analysis of net assets between funds	Unrestricted	Restricted	Total funds
	funds £	funds £	£
Funds balances at 31 December 2015 are			
represented by: Fixed assets	50,362	•	50,362
Net current assets	470,925	137,766	608,691
Provisions	(24,000)		(24,000)
Charity funds at 31 December 2015	497,287	137,766	635,053

# 13. Related party transactions

There were no related party transactions during the year (2014: none).

## 14. Operating Leases

	203	15	201	.4
	Land and	Office	Land and	Office
	<b>Buildings</b>	Equipment	Buildings	Equipment
	£	£	£	£
< 1 year	83,189	981	83,189	1,474
2-5 years	113,407	3,433	193,459	614
> 5 years				
, s years	196,596	4,414	<u>276,648</u>	2,088
15. Financial instruments			2015	2014
			£	£
Basic financial assets			620,370	275,525
Basic financial liabilities			123,420	145,725

Basic financial assets are all debtors plus cash in hand minus prepayments.

Basic financial liabilities are all creditors less due in less than one year plus creditors due in more than one year minus taxation payable.



# 15. Financial instruments (Continued)

The entity's income, expense, gains and losses in respect of financial instruments are summarised below:

below:	2015	2014
	£	£
Total interest income for basic financial assets	1,562	388

# 16. Statement of Financial Activities – comparative figures by fund type

# Year ended 31st December 2014

	Unrestricted		2014 Total
Note			Total
	£	£	£
		070.056	746.063
		278,856	716,062
	1,001,265	1-0	1,001,265
	388	3	388
	2,069	9,320	11,389
	1,440,928	288,176	1,729,104
			750 560
			758,568
			934,860
	1,345,983	347,445	1,693,428
	94,945	(59,269)	35,676
	<u> </u>	•	#i
	94,945	(59,269)	35,676
	115,596	126,667	242,263
	210,541	67,398	277,939
	Note	Note Funds £  437,206 1,001,265 388 2,069 1,440,928  758,568 587,415 1,345,983  94,945  94,945  115,596	Note Funds £  437,206 278,856 1,001,265 388 2,069 9,320 1,440,928 288,176  758,568 587,415 347,445 1,345,983 347,445 94,945 (59,269)  94,945 (59,269) 115,596 126,667



Bowel Cancer UK would like to thank all of our Corporate Partners and Trust & Foundation supporters for their generosity including:

- Charles Russell Speechlys LLP
- Edwards & Co. Solicitors
- Stratas Business Solutions
- Novosco Limited
- 80ver8
- Modern Democracy Limited
- BGC Partners
- Yakult
- Sunsweet Growers Inc.
- Lewis PR
- Norgine Pharmaceuticals
- Merck Serono
- Securicare
- CliniMed
- Dansac Limited
- ConvaTec Limited
- Olympus Keymed
- CUI Wear
- Lifescan Limited
- Waitrose Limited
- Sirtex Medical Limited
- The Hugh Fraser Foundation
- The Simon Gibson Charitable Trust
- The E M Whittome 2013 Charitable Trust
- Kells Trust
- The Valentine Charitable Trust
- The Charles Skey Charitable Trust
- Brian Wilson Charitable Trust
- The Light Fund Company
- The Peacock Charitable Trust
- Miss M B Reekie's Charitable Trust
- R U B White Charitable Trust
- The Tom and Sheila Springer Charity
- Scottish Executive's Section 16B Grant Scheme
- Lloyds Bank Foundation for Northern Ireland
- Big Lottery Fund's Awards For All England

